CJC-1295 NO-DAC (5 mg Vial) Dosage Protocol

Educational guide for reconstitution and daily dosing of CJC-1295 NO-DAC, a GHRH analog studied for growth hormone optimization.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (3 mL = 1.67 mg/mL)

Frequency: Inject once daily subcutaneously. CJC-1295 NO-DAC has a half-life of approximately 30 minutes, supporting daily dosing for optimal GH pulsatility. Note: A single 5 mg vial provides approximately 16–28 days of research material at maintenance doses.

Reconstitution Steps

1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.

How This Works

CJC-1295 NO-DAC (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability.

By inhibiting NNMT, CJC-1295 NO-DAC may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.

Potential Benefits & Side Effects

Observations from preclinical and early research literature.

• May support reductions in fat mass while preserving lean muscle in animal models
• Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies
• Enhanced grip strength observed in aged mice when combined with exercise
• Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions
• Long-term human safety data not established; this compound remains investigational

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. Slow injection may minimize any stinging sensation associated with the compound.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each administration; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
• Document daily dose and site rotation to maintain consistency.
• The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.

References